ReviewPediatric endocrinology, diabetes, and metabolism2026
Recombinant growth hormone therapy in a patient with brachydactyly: case report with literature review.
Review in Pediatric endocrinology, diabetes, and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brachydactyly is a very rare congenital defect involving shortened fingers and/or toes. It can be a component of congenital or genetic syndromes, but it can also occur as an isolated defect, most often inherited in an autosomal dominant pattern. The current classification includes five main types of the disease (A-E) depending on the characteristic constellation of affected fingers and bones. According to the literature, some types may also be associated with height deficiency. To our best knowledge, this article is the first documented example of the effects of recombinant human growth hormone (rhGH) therapy on a child with short stature and brachydactyly type C with normal growth hormone secretion in stimulation tests. In this paper, we present the boy's good response to the treatment and the safety of this therapy, as well as a review of the current literature regarding rhGH therapy in children with isolated brachydactyly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.